Recall Enforment Report D-0939-2023

Recall Details

Drug Recall Enforcement Report Class II voluntary initiated by Glenmark Therapeutics, Inc., originally initiated on 05-01-2023 for the product Famotidine Tablets, USP, 20mg, 200-count bottle within a carton, Distributed by: Glenmark Therapeutics Inc., USA, Mahwah, NJ 07430, Made in India, NDC 72657-113-20. The product was recalled due to labeling: label error on declared strength: some cartons labeled and containing 20 mg may have an external label placed on the side of the carton indicating strength as 10 mg.. The product was distributed nationwide and the recall is currently terminated.

Field Name Field Value
Event ID 92565 What is the Event ID?
A numerical designation assigned by FDA to a specific recall event (used for tracking purposes).
Recall Number D-0939-2023 What is the Recall Number?
An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes).
Recall Classification Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification?
Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified".
Distribution Pattern Nationwide in the USA What is the Distribution Pattern?
General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included.
Product Description Famotidine Tablets, USP, 20mg, 200-count bottle within a carton, Distributed by: Glenmark Therapeutics Inc., USA, Mahwah, NJ 07430, Made in India, NDC 72657-113-20.
Reason For Recall Labeling: Label Error on Declared Strength: some cartons labeled and containing 20 mg may have an external label placed on the side of the carton indicating strength as 10 mg. What is the Reason for Recall?
Information describing how the product is defective.
Product Quantity 19,968 bottles Product Quantity
The amount of product subject to recall.
Voluntary Mandated Voluntary: Firm initiated Voluntary / Mandated
Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order.
Report Date 07-26-2023
Recall Initiation Date 05-01-2023 What is the Recall Initiation Date?
The date that the firm first began notifying the public or their consignees of the recall.
Termination Date 09-17-2024 What is the Date Terminated?
The date that FDA terminated the recall.
Initial Firm Notification N/A Initial Firm Notification of Consignee or Public
The method(s) by which the firm initially notified the public or their consignees of a recall.
Product Type Drugs
Recalling Firm Glenmark Therapeutics, Inc.
Code Info FA2022001B, Exp 03/2025 Code Information
A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling.
Recalled NDC Packages 72657-112-90; 72657-112-20; 72657-113-88; 72657-113-20; 72657-132-01
Status Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard.

Recalled Products

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Product Type
72657-112Famotidine FamotidineTablet, Film CoatedOralGlenmark Therapeutics Inc., UsaHuman Otc Drug
72657-113Famotidine FamotidineTablet, Film CoatedOralGlenmark Therapeutics Inc., UsaHuman Otc Drug
72657-132Famotidine FamotidineTablet, Film CoatedOralGlenmark Therapeutics Inc., UsaHuman Otc Drug